Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: Mass Spectrom Rev. 2009;28(5):703–724. doi: 10.1002/mas.20205

Figure 10.

Figure 10

Graphic depiction of the discovery of potential biomarkers for diabetic nephropathy. CE-MS datasets from control and patients with prostate cancer, bladder cancer, and cardiovascular disease are compared to data obtained from patients with diabetic nephropathy (1) using appropriate statistics (adjustments for multiple testing as described in, e.g., (Westfall and Young, 1993; Benjamini and Hochberg, 1995; Reiner et al., 2003; Abdi, 2007)). Potential biomarkers that show significant differences in amplitude and/or distribution (2) are located in the database (3). The clustering of the biomarker (with respect to deviation) is examined in comparison to neighboring peptides (4). If found appropriate, ID, mass, normalized migration time, and, if known, sequence can be retrieved from the database (5). Reprinted with permission from (Coon et al., 2008).